<div id="readability-page-1"><div>Gaithersburg, Maryland--(Newsfile Corp. - January 13, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (&#34;Shuttle Pharma&#34; or the &#34;Company&#34;), applauds the state of Utah which has become the first state in the United States to allow artificial intelligence systems to authorize prescription refills without direct physician involvement — a regulatory first that signals how AI is beginning to reduce healthcare costs, eliminate delays, and expand access to care.The pilot program, launched through Utah's Office of Artificial Intelligence Policy and powered by Doctronic, allows AI to refill certain commonly prescribed medications for chronic conditions. Proponents argue that the model saves patients time and money, particularly in rural areas where physician shortages can turn routine refills into weeks-long delays and costly clinic visits.While limited to refills and governed by strict oversight, the initiative reflects a broader shift across healthcare: AI is being trusted to automate repetitive, high-volume decisions — freeing human experts to focus on complex, high-value work.That same principle is at the core of what we believe Shuttle Pharma's Molecule.ai platform is building in drug discovery.Automating the Bottlenecks That Cost Time and MoneyIn clinical care, prescription refills are time-consuming, expensive, and often redundant. In drug development, similar bottlenecks occur much earlier in the development process — during molecular screening, during candidate prioritization, and during failed late-stage experiments that are costly.Molecule.ai applies AI to minimize these inefficiencies by dramatically reducing:<ul><li>Time to identify viable drug candidates;</li><li>Cost of failed experiments and late-stage attrition; and</li><li>Human labor spent on repetitive screening and analysis.</li></ul>The Molecule.ai platform leverages advanced Agentic AI to predict molecular properties, model drug-target interactions and prioritize compounds before they ever reach the lab. We believe that what once required months of manual experimentation could now be narrowed to days — at a fraction of the cost.Just as Utah's AI refill system automates routine prescribing decisions, Molecule.ai automates the most resource-intensive steps of drug discovery, allowing scientists to focus on breakthrough innovation rather than trial-and-error.Built for Scale, Safety, and OversightCritics of Utah's pilot program warn that AI could miss subtle warning signs or be misused. These concerns highlight a central truth: AI must be designed not only for speed, but for accountability.Molecule.ai addresses these concerns by embedding:<ul><li>Uncertainty quantification, so low-confidence predictions are flagged</li><li>Human-in-the-loop workflows, ensuring expert oversight at critical decision points</li><li>Explainable models, enabling teams to understand why a molecule is prioritized</li></ul>This mirrors Utah's regulatory sandbox approach, where AI is allowed to operate within clear boundaries, escalate edge cases to humans, and demonstrate safety before wider adoption.The Economic Case for AI in Healthcare and Drug DiscoveryThe healthcare and biopharmaceutical industries face the same economic reality: rising costs, limited human resources, and growing demand. We believe AI can offer a path to sustainability.<ul><li>For patients, we believe AI can reduce unnecessary visits, wait times, and out-of-pocket costs.</li><li>For healthcare systems, we believe AI lowers operational burden and improves access.</li><li>For drug developers, we believe AI can cut R&amp;D timelines, reduce capital burn, and increase the probability of clinical success.</li></ul>Molecule.ai is designed to deliver these savings at scale — transforming AI from a research tool into core infrastructure for modern drug development.A Glimpse of the FutureUtah officials have said results from the AI prescription pilot will help shape future state and federal AI policy, potentially serving as a national model for high-stakes AI regulation in healthcare.As regulators grow more comfortable granting AI limited authority where it demonstrably saves time and money without sacrificing safety, the industry will increasingly demand AI platforms that are robust, auditable, and economically transformative.That is the future Shuttle Pharma is building toward with the Molecule.ai platform:AI that accelerates discovery, lowers costs, and brings better therapies to patients faster — safely and responsibly.About Shuttle PharmaShuttle Pharmaceuticals Holdings, Inc. owns a pharmaceutical software artificial intelligence (&#34;AI&#34;) driven platform for molecular discovery and early-stage drug development. By combining modern AI techniques with structured scientific workflows, the Molecule.ai platform helps researchers explore the chemical space more efficiently, evaluate molecular ideas with greater clarity and make more informed decisions during the earliest stages of drug development.Cautionary Note Regarding Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute &#34;forward-looking statements.&#34; These statements include, but are not limited to, statements concerning the development of our company and the Molecule.ai platform. The words &#34;anticipate,&#34; &#34;believe,&#34; &#34;continue,&#34; &#34;could,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;may,&#34; &#34;plan,&#34; &#34;potential,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;should,&#34; &#34;target,&#34; &#34;will,&#34; &#34;would&#34; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the &#34;Risk Factors&#34; section of Shuttle Pharma's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025, as well as other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharma disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.Shuttle PharmaceuticalsChris CooperChief Executive Officerinfo@shuttlepharma.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/280266</div></div>

SHPH

Utah has become the first U.S. state to allow AI systems to authorize prescription refills without direct physician involvement, aiming to reduce healthcare costs and improve access. Shuttle Pharmaceuticals' Molecule.ai platform applies AI to streamline drug discovery, minimizing inefficiencies and costs associated with drug development. The initiative reflects a broader trend in healthcare towards automating routine decisions, while ensuring accountability and safety through expert oversight. The pilot program's results may influence future AI regulations in healthcare, promoting AI as a transformative tool in drug development.

Utah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs - and Why Molecule.ai's Drug Discovery Platform Matters More Than Ever